-
The multi-target inhibitor introduced by Zai Lab over US$350 million received clinical approval for the first time
Time of Update: 2022-01-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 23, the CDE official website showed that Turning Point's TPX-0022 capsule clinical trial application was approved by the Food and Drug Administration for the treatment of locally advanced or metastatic non-small cell lung cancer, gastric cancer or solid tumors with MET gene mutations .
-
The selection criteria for dual-channel pharmacies are here!
Time of Update: 2022-01-14
In accordance with the requirements of the National Medical Insurance Administration, the medical insurance departments of all regions must adhere to the principle of “openness, fairness, and justice”, determine the selection criteria and procedures, and ensure that the qualifications are compliant, the management practices, the reputation is good, the layout is reasonable, and the Designated retail pharmacies with retrospective conditions are included in the "dual channel" management, and they are proactively disclosed to the public in a timely manner .
-
BeiGene's TYK2 inhibitor enters the clinic and expands its layout in the field of inflammation and immunology
Time of Update: 2022-01-14
On November 22, 2021, BeiGene announced that the first patient in a phase 1 clinical trial of the potent tyrosine kinase 2 (TYK2) inhibitor BGB-23339 under investigation has been administered .
-
Milestone of new drug for cholangiocarcinoma: progress in FGFR2 inhibitor research and development
Time of Update: 2022-01-14
In April 2020, the FDA accelerated the approval of pemigatinib developed by Incyte Biopharmaceuticals in the United States for use in adult patients with unresectable locally advanced or metastatic cholangiocarcinoma who have previously been treated and carry FGFR2 gene fusion or other rearrangements.
-
Roche announces the latest results of multiple bispecific antibodies and ADC therapies
Time of Update: 2022-01-14
The clinical trial data described in the ASH summary showed that glofitamab, as a single-agent therapy, achieved 81% ORR (n=43) and 70% complete metabolic remission in early clinical trials for the treatment of patients with relapsed/refractory follicular lymphoma Rate (CMR) .
-
Hengrui people have license in. Who will find the new drug king?
Time of Update: 2022-01-14
How to find a new drug king?Recently, the Sci-tech Innovation Edition has rejected several biopharmaceutical companies, and a huge wave has been set off among innovative drug companies that are alread
-
Sanofi and Baidu collaborate to develop mRNA vaccines and partner with Owkin to deploy AI pharmaceuticals
Time of Update: 2022-01-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, Sanofi reached two collaborations to develop new therapies for 4 specific types of cancers (non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma) with Owkin; obtained Baidu mRNA sequence design Algorithm (LinearDesign technology) for the design of vaccines and therapeutic products .
-
How is the transformation of Bigpharma's CSPC Group?
Time of Update: 2022-01-14
Source: Zhongkang FIC Intelligence database02 "Creation + imitation" dual engine accelerates to seize the market02 "Creation + imitation" dual engine accelerates to seize the marketIn recent years, CSPC has continuously increased R&D investment, focusing on R&D and innovation .
-
Alis Medical's third-generation EGFR-TKI plans to be included in breakthrough treatment products
Time of Update: 2022-01-14
ArticleMedicine GuanlanOn November 23, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the third-generation EGFR-TKI vometinib mesylate tablets of Allis Pharmaceuticals will be included in the breakthrough treatment product, and the proposed indication is : First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) replacement mutation .
-
U.S. FDA suspends clinical trials of Kura's leukemia drug KO-539 due to death of 1 patient
Time of Update: 2022-01-13
According to the announcement issued by Kura, the FDA has suspended the phase 1b trial of KOMET-001, which evaluates KO-539 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) .
-
The modern age of chemical medicine: a brief biography on fluoxetine
Time of Update: 2022-01-13
By 1976, when the animal safety study was over, Eli Lilly submitted a new drug clinical trial (IND) application for fluoxetine to the FDA .
A 5-week multicenter double-blind randomized controlled trial compared the efficacy of fluoxetine with the TCA drug amitriptyline in the treatment of major depression .
-
Pioneering pharmaceutical innovative therapies for the treatment of androgenetic alopecia start phase 3 clinical trials in China
Time of Update: 2022-01-13
On November 24, 2021, Kintor Pharma announced that its potential "first-in-class" new drug Furitan (KX-826) for the treatment of male androgenetic alopecia (AGA) Phase 3 clinical trials The trial application has been approved by the National Medical Products Administration (NMPA) of China .
-
FDA: Critical Path for Generic Drug Development
Time of Update: 2022-01-13
Critical PathIn order to more effectively develop high-quality generic drugs to improve public health, the FDA has identified the following four key paths:Improvements in the above aspects will accelerate the listing of generic drugs .
-
The clinical trial application of Haisco's innovative drug HSK31858 tablets was accepted by the State Food and Drug Administration
Time of Update: 2022-01-13
On November 29, Haisco issued an announcement stating that the company had recently received the "Notice of Acceptance" for HSK31868 tablets issued by the National Medical Products Administration .
In addition, there is no clinical research on the same target product globally .
-
Anti-allergic drugs and miraculous anti-cancer functions are expected to solve the problem of patient insensitivity to drugs
Time of Update: 2022-01-13
Using the cancer gene map and patient data, the researchers found that when tumors highly express HRH1, the function of T cells will also be disordered, which is related to the poor efficacy of checkpoint inhibitors and decreased survival rates .
-
Hutchison Medicine and AstraZeneca initiate phase 3 clinical trials of combination therapy in China
Time of Update: 2022-01-13
Retrieved November 23, from https:// /2021/11/24/2340238/0/en/HUTCHMED-and-AstraZeneca-Initiate-SACHI-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-in -China-After-Progression-on-EGFR-Inhibitor-Therapy.
html[2] Hutchison Medical and AstraZeneca initiated the SACHI China Phase III clinical trial of the combined therapy of ORPATHYS® (ORPATHYS®) and Teresa® (TAGRISSO®) in the treatment of specific lung cancer patients with disease progression after EGFR inhibitor treatment.
-
More than 6 billion people have returned to the market in five years and attacked innovative drugs!
Time of Update: 2022-01-13
Figure 1: Changes in the revenue share of Renfu Medicine's various business segments in recent yearsSource: Company Annual ReportAccording to annual report data, pharmaceutical manufacturing, pharmaceutical wholesale and related businesses have always been the two major operating sectors of Human Welfare Pharmaceuticals, but their gross profit margins are far from each other .
-
Changes in Hengrui Medicine: "Honesty people" begin to liven up their minds
Time of Update: 2022-01-13
The author believes that whether it is the capitalization of R&D investment or the repeated introduction of innovative drugs that are about to be produced, various behaviors mean that the thinking of "honest people" Hengrui Medicine has begun to become more active .
-
Fosun Pharma’s MEK1/2 inhibitor initiates phase II clinical treatment for type I neurofibromas
Time of Update: 2022-01-13
Article source: Medical Rubik's Cube InfoRecently, Fosun Pharma issued an announcement stating that it has initiated a phase II clinical study of FCN-159 tablets for the treatment of type I neurofibromas .
-
Haixiang Pharmaceutical: Hire Academician Chen Fen'er as the company's chief scientist
Time of Update: 2022-01-13
Academician Chen Fen'er is an academician of the Chinese Academy of Engineering, a professor and doctoral supervisor of Fudan University.
He has long been engaged in synthetic medicinal chemistry and pharmaceutical engineering research, and has made extraordinary achievements in pharmaceutical manufacturing, fine organic chemicals and engineering .
